UNITED KINGDOM (UK) DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

UNITED KINGDOM (UK) DIABETES DRUGS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

During the forecast period 2022-2027, the United Kingdom Diabetes Drugs Market is set to witness a CAGR of more than 3%.

The COVID-19 pandemic has had a substantial impact on the United Kingdom’s diabetes drugs market. According to The British Diabetic Association, “The pandemic has had and continues to have, a huge impact on our society. But research and data have shown that people with diabetes have been disproportionately affected by COVID-19, particularly in terms of poorer outcomes when contracting the virus. That’s why preventing or delaying cases of type 2 diabetes is more important than ever before.” Within the first year since its inception, the COVID-19 pandemic has been responsible for premature deaths, particularly among older individuals. Most people who have died of COVID-19 were affected by the co-occurrence of two or more chronic conditions in the same individual. Several studies have confirmed that chronic diseases like diabetes are associated with adverse outcomes in COVID-19 patients.

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. According to The British Diabetic Association, Diabetes prevalence 2021 data shows an increase in the number of people living with a diabetes diagnosis in the UK: an increase of more than 150,000 from 2020. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.

In May 2021, the World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes. It recommends action in areas including increasing access to insulin; promoting convergence and harmonization of regulatory requirements for insulin and other medicines and health products for the treatment of diabetes; and assessing the feasibility and potential value of establishing a web-based tool to share information relevant to the transparency of markets for diabetes medicines and health products.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsOral Anti-Diabetic Drugs are Expected to Register Highest Growth Rate in the United Kingdom Diabetes Drugs Market

Oral Anti-Diabetic Drugs are expected to dominate the United Kingdom Diabetes Drugs Market with a CAGR of more than 3% and record revenue of about USD 940 million during the forecast period 2022-2027.

The United Kingdom had witnessed an alarming increase in the prevalence of diabetes, in recent years. Patients with diabetes require many corrections throughout the day for maintaining nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. According to The British Diabetic Association 2021 data, it is estimated that more than 13.6 million people are at increased risk of type 2 diabetes in the UK. At this rate, the number of people with diabetes, including the undiagnosed population, is expected to rise to 5.5 million by 2030.

Oral Anti-Diabetic Drugs have been available internationally and are recommended for use when escalation of treatment for type 2 diabetes is required along with lifestyle management. Oral agents are typically the first medications used in the treatment of type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help diabetes patients to keep their condition under control and lower the risk of diabetes complications. People with diabetes may need to take antidiabetic drugs for their whole lives to control their blood glucose levels and avoid hypoglycemia and hyperglycemia. Oral anti-diabetic agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

Any medicinal product commercially available in the UK is eligible for reimbursement which means the NHS refunds the costs of the medicine to the dispensing pharmacist or doctor apart from a few exceptions. Various steps are being taken in the direction to control diabetes. An electronic version of a personalized Diabetes UK Management Plan is available for completion on EMIS Web. The plan can be used to record the objectives and steps agreed upon with the patient and generate an Information Prescription. The Information Prescription can be printed out and given to the patient and an electronic version saved in the patient’s care record. The Diabetes UK Management Plan protocols need to be activated and generate a pop-up alert for patients if they are pregnant, have kidney disease, or have a raised BP/HbA1c/Cholesterol value, and no record of a diabetes management plan in the last 6 months, no record of an eGFR or ACR test in the last 13 months and no record of a Patient Health Questionnaire recorded in the last 3 months.

Owing to the aforementioned factors it is likely that the market will continue to grow.

Glucagon-like Peptide-1 Receptor Agonist Segment is Expected to Dominate the United Kingdom Diabetes Drugs Market in terms of revenue

Glucagon-like Peptide-1 Receptor Agonist Segment is expected to dominate the United Kingdom Diabetes Drugs Market in terms of revenue and register a CAGR of more than 2.5% during the forecast period.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over older insulin secretagogues, such as sulfonylureas or meglitinides, is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes’ composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

The Association of British HealthTech Industries (ABHI) is a trade association for the medical technology sector in the UK. The National Service Framework (NSF) program is improving services by setting national standards to drive up service quality and tackle variations in care. The Association of British HealthTech Industries launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind. The ABHI group is for any health technology company with an interest in diabetes care.

The growing incidence, prevalence, and progressive nature of the disease have encouraged the development of new drugs to provide additional treatment options for diabetic patients. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some of the market opportunities for the players in the UK diabetes drugs market.

Competitive Landscape

The United Kingdom Diabetes Drugs Market is consolidated, with major manufacturers namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding a presence in the region. A major share of the market is held by manufacturers that are concomitant with strategy-based M&A operations and are constantly entering the market to generate new revenue streams and boost existing ones. These measures taken by the market players will ensure a competitive marketplace, therefore, forcing the companies to experiment with more new technologies.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.